WildersH., GuetensG., De BoeckG.: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT11. Br J Cancer, 88: 1979, 2003.
2.
JainRK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med, 7: 987–989, 2001.
3.
MinagawaN., NakayamaY., HirataK.: Correlation of plasma level and immunohistochemical expression of VEGF in patients with advanced colorectal cancer. Anticancer Res, 22: 2957–2963, 2002.
4.
WongM.P., CheungN., YuenS.T.: VEGF is up-regulated in the early pre-malignant stage of colorectal tumor progression. Int J Cancer, 81: 845–850, 1999.
5.
DvorakHF: Vascular permeability factor/VEGF: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 20: 4368–4380, 2002.
6.
ZhengS., HanM.Y., XiaoZ.X.: Clinical significance of VEGF expression and neovascularization in colorectal carcinoma. World J Gastroenterol, 9: 1227–1230, 2003.
7.
CarboneJ.E., OhmDP: Immune dysfunction in cancer patients. Oncology (Huntingt), 16: 11–18, 2002.
8.
HurwitzH., FehrehnbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342, 2004.
9.
GiantonioB.J., CatalanoP.J., MeropolN.J.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from Eastern Cooperative Oncology group study E3200. Proc ASCO, 24: abst 2, 2005.
10.
JohnsonD.H., FehrenbacherL., NowotnyW.F.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 22: 2184–2191, 2004.
11.
SandlerA.B., GrayR., BrahmerJ.: A randomized phase III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non squamous NSCLC: an ECOG trial E4599. Proc ASCO, 24: abst LBA4, 2005.
12.
MillerK.D., WangM., GralowJ.: E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at 2005 ASCO Annual Meeting.
